Skip Navigation

This Article
Right arrow Full Text (PDF )
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (7)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Recabarren, S. E.
Right arrow Articles by Wildt, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Recabarren, S. E.
Right arrow Articles by Wildt, L.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Human Reproduction, Vol. 6, No. 7, pp. 928-930, 1991
© 1991 European Society of Human Reproduction and Embryology

other

Plasma luteinizing hormone bioactivity and immunoactivity in ovariectomized rats treated with a long-acting agonist of luteinizing hormone releasing hormone

S. E. Recabarren1, R. Dittrich, W. Jäger and L. Wildt

Department of Obstetrics and Gynaecology, University of Erlangen 8520 Erlangen, FRG

Correspondence: 1To whom correspondence should be addressed

The dose response of a luteinizing hormone releasing hormone (LHRH) agonist in rats with high endogenous gonadotrophin levels was determined. Female rats were ovariectomized and injected with 0.3 µg (group B), 3.2 µg (group C), 32 µg (group D) and 320 µg (group E) of a slow-releasing micro-capsule preparation of the LHRH agonist D-Trp 6-LHRH. Control ovariectomized rats (group A) remained untreated. Plasma luteinizing hormone (LH) concentrations were measured by radiounmunoassay (RIA) before the LHRH agonist injection as well as 5, 15 and 30 days thereafter. Furthermore, LH bioactivity was determined by an in vitro rat LH bioassay in order to evaluate changes in bioactivity after administration of LHRH agonist. In control rats, plasma LH concentrations increased to 4.8 ± 1.3 ng/ml on day 5, reaching peak levels of 9.9 ± 1 ng/ml on day 30. In contrast to the control group, those rats which received 320 µg of LHRH agonist did not show any increase. Rats which received intermediate doses (groups C and D) tended to maintain levels of LH halfway between group A and group E during the first 15 days of treatment. Thereafter LH concentrations were similar to the untreated control group. The course of the LH concentrations during treatment measured by bioassay (BA) showed a similar pattern to the LH concentrations measured by RIA. The BA/RIA ratio was similar in all groups.

Key words: bioactive LH/LHRH analogue/microcapsule/D-Trp 6-LHRH ovariectomized rats


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 ReproductionHome page
T. Maltaris, M. W Beckmann, H. Binder, A. Mueller, I. Hoffmann, H. Koelbl, and R. Dittrich
The effect of a GnRH agonist on cryopreserved human ovarian grafts in severe combined immunodeficient mice
Reproduction, February 1, 2007; 133(2): 503 - 509.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.